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Allergic diseases, orchestrated by hyperactive CD4+ Th2 cells, are
some of the most common global chronic diseases. Therapeutic
intervention relies upon broad-scale corticosteroids with indiscrim-
inate impact. To identify targets in pathogenic Th2 cells, we took
a comprehensive approach to identify the microRNA (miRNA) and
mRNA transcriptome of highly purified cytokine-expressing Th1,
Th2, Th9, Th17, and Treg cells both generated in vitro and isolated
ex vivo from allergy, infection, and autoimmune disease models.
We report here that distinct regulatory miRNA networks operate
to regulate Th2 cells in house dust mite-allergic or helminth-infected
animals and in vitro Th2 cells, which are distinguishable from other
T cells. We validated several miRNA (miR) candidates (miR-15a,
miR-20b, miR-146a, miR-155, and miR-200c), which targeted a suite
of dynamically regulated genes in Th2 cells. Through in-depth
studies usingmiR-155 −/− ormiR-146a−/− T cells, we identified that
T-cell–intrinsic miR-155 was required for type-2 immunity, in part
through regulation of S1pr1, whereas T-cell–intrinsic miR-146a
was required to prevent overt Th1/Th17 skewing. These data iden-
tify miR-155, but not miR-146a, as a potential therapeutic target to
alleviate Th2-medited inflammation and allergy.
CD4
+ T cells can differentiate into various Th subsets char-
acterized by distinct molecular programs and cytokine pro-
duction, e.g., IFN-γ–secreting Th1 cells, IL-4–secreting Th2 cells,
and IL-17A–secreting Th17 cells. Specifically, IL-4 signaling in
naive T cells activates STAT6 and GATA3 (1), promoting a Th2
differentiation pathway by activating transcription at the Il4, Il5,
and Il13 loci (2). Characteristically, Th2 cells have a detrimental
role in allergies, which are becoming one of the most common
global chronic diseases (3). In contrast, Th2 cells are essential for
antihelminth immunity (4). Despite a good understanding of the
signals required for Th2 differentiation (1), our knowledge of the
molecular mechanisms involved in the posttranscriptional regu-
latory events that govern Th2 cell differentiation and effector
function remain unclear.
microRNAs (miRNAs), encoded within the genome and cleaved
by two ribonuclease-III enzymes, Dicer and Drosha (5), regulate
mRNA translation by inhibiting and degrading mRNA (6).
miRNAs critically shape immune cell development and function
(7, 8) with targeted deletion of Dicer in T cells resulting in di-
minished peripheral CD8 and CD4 T cells (9). Among the
∼2,000 identified mammalian miRNAs (miRbase v20) (10),
several T-cell–associated miRNAs have been identified that
regulate development (11), differentiation (12–14), and effector
function (15–19). For example, miR-29 and miR-21 regulate
Th1-mediated immunity (13, 17, 18), whereas miR-326 (20),
miR-10a (21), miR-155 (22), and miR-132/212 (23) influence
Th17 cell differentiation and effector function. Treg cells, which
provide a critical brake on effector responses, also are governed
by miRNAs (24, 25), with miR-182, miR-10a (21, 26), miR-155
(27), and miR-146a (16) required for proficient Treg development
and suppressive capacity. Several studies have identified miRNAs,
including miR-126 (28), miR-106a (29), miR-145 (32), miR-221,
and miR-155/205/498/Let-7e (30), in murine (28, 29) and human
(30) allergic diseased tissue (31); however, there is a scarcity of
studies specifically identifying miRNA-mediated regulation of
Th2 cell differentiation and effector function. Correlations of
elevated miR-181a, miR-146a, and miR-146b expression in dis-
tal, splenic CD4+ cells during experimental ovalbumin (OVA)-
induced airway inflammation have been reported (33) but have
not been tested. To date, only miR-155 has been implicated in
Th2 differentiation in vitro (34), leaving a significant gap in our
understanding of miRNAs involved in Th2 cell differentiation
and in vivo effector function.
In this study we took a systematic and comprehensive approach
to identify the miRNAome of all Th cells, using highly purified
cytokine or transcription factor reporter systems to identify Th2-
specific miRNAs. Using a subtractive comparative analysis, we
established distinct transcriptomes, miRNAs, and their targets in
Th2 cells generated in vitro and isolated ex vivo from house dust
mite (HDM)- or helminth (Heligmosomoides polygyrus)-induced
inflammation that were distinct from other Th subsets. Func-
tionally restricting miR-155 or miR-146a deficiency to T cells by
using mixed bone marrow chimeras or miRNA inhibitors and
adoptive transfer systems, we identified opposing roles for miR-
155 and miR-146a in respectively promoting and regulating Th2-
driven immunity. Collectively these data identify critical roles for
miR-155 and miR-146a in Th2-mediated immunity and suggest
that targeting miR-155, but not miR-146a, may alleviate Th2-
mediated inflammation and asthma.
Significance
The rising prevalence of allergic diseases throughout the world
demands new approaches to treat this inflammatory disorder.
CD4+ Th2 cells orchestrate the allergic cascade, stimulating IgE
production, activating innate cells, and stimulating local tissue.
This study took a comprehensive approach to identify the unique
transcriptional features of pathogenic Th2 cells with the aim of
identifying novel molecular regulators. Highly purified Th1, Th2,
Th9, Th17, and Treg cells isolated from mice with allergy, in-
fection, and autoimmunity identified unique mRNA and micro-
RNAs (miRNAs) expressed in Th2 cells. Functional and mechanistic
studies using miRNA-deficient mice, luciferase assays, miRNA
inhibitors, and siRNA in combination with state-of-the-art adop-
tive transfer systems, identified a critical role for miR-155–regu-
lated S1pr1 in the pathogenesis of Th2-mediated allergy.
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Results
Using Purified Cytokine/Transcription Factor Reporter-Positive Cells,
Rather than Whole T-Cell Cultures, Increases Sensitivity and Resolution
of Transcriptional Profiling. To identify differentially regulated
miRNAs in differentiated T cells, we initially used the well-
studied in vitro T-cell activation and differentiation system (35)
(Fig. 1A and SI Appendix, Figs. S1 and S2A). In the absence of
supraphysiological restimulation with phorbol12-myristate13-
acetate (PMA) and ionomycin, we obtained ∼75% of cells
committed to a Th2 phenotype as determined using Il4gfp ex-
pression. However, the percentage of other in vitro polarized
cells varied [∼70% Th1, ∼27% Th17, 70% Th9, and 85% in-
duced Treg (iTreg)]. Thus, between 73–15% of cells within each
bulk population were not polarized or committed (SI Appendix,
Fig. S2A). Therefore we used the transcriptional reporter mice
(Ifnγyfp, Il4gfp, Il9CreR26eYFP, Il17aCreR26FP635, and Foxp3rfp) to
purify live, unfixed, and nonpermeabilized reporter-positive
cells, eliminating the influence of nonpolarized cells and avoid-
ing the use of PMA and ionomycin in our transcriptional anal-
ysis. Purified reporter-positive cells revealed dramatically more
differentially expressed genes and miRNAs with a greater dy-
namic range (fold change), than the bulk cultures (SI Appendix,
Fig. S1 A and B). In particular, in Il4gfp+ Th2 cells we identified
4,644 differentially regulated genes and 137 miRNAs (an in-
crease of more than twofold relative to naive T cells), compared
with 1,926 genes and 46 miRNAs in bulk Th2 polarized cells (SI
Appendix, Fig. S2B and Table 1), with many genes involved in IL-
4 signaling that were undetected in bulk Th2 polarized cells (SI
Appendix, Fig. S2 B and C). In all subsets, Th cell-associated
transcription factors [Tbx21 (Th1), Rorγt (Th17), Foxp3 (Treg),
and Irf4 and E4bp4 (Th2)] were up-regulated to a greater degree
in purified cells than in bulk Th2 polarized cells.
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Fig. 1. Transcriptional analysis of FACS-purified
reporter-positive T cells reveals overlap with ex vivo
cells and identifies significant diversity between
Th2 populations. Naive CD4 T cells were polarized
in vitro, as described in Materials and Methods,
with mRNA and miRNA transcriptional profiles
used for comparative analysis. (A) Heat maps
showing expression of mRNA (Left) and miRNAs
(Right) in in vitro-derived T-cell subsets. Each
heatmap lane represents the mean of three to five
biological replicates per T-cell subset. (B) Heat maps
showing expression of mRNA (Left) and miRNAs
(Right) in ex vivo-derived T-cell subsets. Each
heatmap lane represents the mean of three to five
biological replicates per T-cell subset. (C) Compar-
ative analysis showing common and unique mRNA
(Left) and miRNA (Right) transcripts in each T-cell
subset (greater than a fivefold change). Unique
transcripts in ex vivo HDM-derived Th2 cells are
highlighted in the red square. (D) Selection of HDM-
derived Th2-enriched mRNAs (Left) and miRNAs
(Right). (E) Venn diagrams showing comparative
analysis of common and unique mRNA (Left) and
miRNA (Right) transcripts in the in vitro and ex vivo
T-cell subsets (greater than a fivefold change). The
percentage of overlap is shown in blue. (F) Venn
diagrams showing comparative analysis of com-
mon and unique Th2-enriched mRNA (Left) and
miRNA (Right) transcripts in the in vitro and ex vivo
T-cell subsets (greater than a fivefold change). The
percentage of overlap is shown in blue. (G) Heat
maps showing expression of mRNA (Left) and
miRNAs (Right) in Th2 cell subsets from allergic
HDM-challenged mice and mice susceptible (H.p. 1°)
and resistant (H.p. 2°) to H. polygyrus. (H) (Left) Total
number of differentially regulated mRNA tran-
scripts (greater than a fivefold change) in different
Th2 samples. (Right) Number of differentially reg-
ulated miRNA transcripts (greater than fivefold
change) in different Th2 samples. Each heatmap
lane represents the mean of three to five biological
replicates per T-cell subset. (I) Four-way Venn dia-
grams showing comparative analysis of common
and unique mRNA and miRNA transcripts in Th2
subsets. Numbers on Venn diagram are the number
of transcripts; letters refer to the bar chart in SI
Appendix, Fig. S7.
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An miRNA and mRNA Signature Distinguishes Th2 Cells from Other Th
and Treg Subsets. Comparing the transcriptomes across all five
purified reporter-positive T-cell subsets generated in vitro (Th1,
Th2, Th9, Th17, and iTreg), we identified a suite of 285 Th2-
enriched genes including Ccr1, Fosb, Ccr2, Socs1, and Il10rα, that
were unchanged in other T-cell subsets (SI Appendix, Fig. S3 A
and B and Table 2). We also applied an increasing fold-change
filter (a two-, five-, or 10-fold change, relative to naive T cells) to
identify highly abundant transcripts that distinguished Th2 cells
from the other T-cell subsets (SI Appendix, Fig. S4). We identi-
fied 38 Th2-enriched miRNAs, including miR-146a, miR-200c,
miR-15a, and miR-1931, that were unchanged in other T-cell
subsets (Fig. 1A and SI Appendix, Fig. S3 A and B and Table 3).
It was reported recently that upon T-cell activation in vitro there
is a down-regulation in global miRNA and miRNA biogenesis
pathways (36). We observed a similar down-regulation (SI Ap-
pendix, Fig. S5A) along with reduced Argonaute, Dicer, and Dgcr8
transcripts (SI Appendix, Fig. S5B). Taken together, this strategy
allowed us to identify more accurately transcripts that were dif-
ferentially regulated in highly purified Th2 cells, and the broad,
comprehensive approach allowed us to distinguish more accu-
rately unique features of Th2 cells.
Transcriptional Diversity Between in Vitro-Differentiated and ex Vivo
Th2 (Il4gfp+) Cells from Helminth-Infected and HDM-Challenged Mice.
To determine how similar in vitro-generated T cells were to their
in vivo counterparts, we purified reporter-positive cells from
various inflammatory settings: Th1 cells (CD4+Ifnγyfp+) from
Plasmodium chabaudi-infected mice, Th2 cells (CD4+Il4gfp+)
from mice with HDM-induced airway inflammation, Th17 cells
(CD4+Il17aCre;R26eFP635+) from mice with experimental autoim-
mune encephalomyelitis (EAE), and natural Treg cells (nTregs)
(CD4+Foxp3rfp+) from naive mice (Fig. 1B). We could not isolate
sufficient Th9 cells ex vivo under any conditions. Using this suite
of highly purified ex vivo T cells, we performed genomewide
transcriptional analysis and identified distinct mRNA and miRNA
expression profiles in ex vivo Th2 cells with 247 Th2-enriched
genes, including Il2, Pros1, Il13, Traip, S1pr1, and five miRNAs
(miR-22, -202, -494, -18a, and -20a) (Fig. 1C and SI Appendix, Fig.
S6 and Table 4).
Strikingly, when we compared purified in vitro-generated Th2
cells with ex vivo HDM-elicited Th2 cells, we observed very little
overlap, with only 20% (267 transcripts) of differentially regu-
lated genes in common (Fig. 1E). Similar percentages were ob-
served for other Th subsets, with even lower concordance (5.4%)
between iTreg and nTreg cells (Fig. 1E). When we compared
Th2-enriched genes (i.e., genes that were differentially regulated
in Th2 cells but not in other T cells) in the in vitro-generated
(285 genes) and in the ex vivo HDM-elicited (247 genes) Th2
cells, we observed an overlap of less than 1%, with only one gene
in common, the polycomb family histone methyltransferase,
Ezh2 (Fig. 1F), previously implicated in Il4 and Il13 gene regu-
lation (37). We did not find any overlap in Th2-enriched miRNAs
between the in vitro and ex vivo Th2 cells. These data highlight the
great discrepancy between in vitro-generated and ex vivo-isolated
T-cell subsets and particularly the poor concordance between in
vitro and ex vivo Th2 cells.
To investigate Th2 cell diversity further and to determine how
transcriptionally different other Th2 cells were, we isolated Th2
cells from mice susceptible (primary infection, H.p. 1°) or re-
sistant (drug-cured and reinfected, H.p. 2°) to infection with the
intestinal helminth H. polygyrus. Genomewide transcriptional
analysis showed that mRNA and miRNA transcripts in these ex
vivo samples were distinct from in vitro Th2 cells and also were
distinct from HDM-elicited Th2 cells (Fig. 1G). A four-way
comparison of all Th2 populations (in vitro, HDM-elicited, H.p. 1°,
and H.p. 2°) using all differentially regulated genes identified only
82 genes and 14 miRNAs in common (Fig. 1I and SI Appendix,
Figs. S7–S10). Together, these data indicate that Il4gfp+ Th2
cells generated in vitro or isolated ex vivo are largely hetero-
geneous, with more unique than overlapping mRNA and miRNA
transcripts.
miRNA Target Prediction Identifies Putative miRNA-Mediated
Regulation of Metabolic, Signaling, and Migration Pathways in Th2
Cells. Given the diversity in each Th2 population, we analyzed
each Th2 population separately to identify Th2-associated miR-
NAs and their mRNA targets. We used several in silico analyses to
screen for putative functional miRNA–mRNA interactions. First
we used an expression-pairing analysis (asking specifically whether
up-regulated miRNAs were predicted to target down-regulated
mRNAs, and vice versa). We then combined this analysis with
a series of fold-change filters (two-, five-, or 10-fold change) in
each Th2 population to identify transcripts that were more
prominently changed in each Th2 subset. Finally, for each putative
miRNA, we assessed the target abundance (i.e., the number of
mRNAs targeted by any given miRNA, which would indicate an
miRNA regulatory hub). For example, using in vitro-generated
Th2 cells with a twofold filter, we identified seven miRNAs
(SI Appendix, Fig. S11A, Left) that both were predicted to target
and had expression patterns opposing 46 mRNAs (SI Appendix,
Fig. S11, Top Right). Of these seven miRNAs, miR-214-3p (which
was increased 3.6-fold from the level in naive T cells) was predicted
to target 21 mRNAs. By increasing the fold-change filter to five-
and 10-fold change, we lost miR-214-3p but identified several other
miRNAs, including miR-15a, which was down-regulated 70-fold
from levels in naive T cells and was predicted to target 22 (fivefold)
and 14 (10-fold) Th2-enriched mRNAs, respectively (boldface in
SI Appendix, Fig. S11A). Of note, miR-15a was down-regulated by
2.3-fold in both Th1 and iTreg cells, explaining why we did not
identify miR-15a in the twofold-cutoff filter.
Combining these analyses from the in vitro-generated Th2
cells (SI Appendix, Fig. S11A), HDM-induced Th2 cells (SI Ap-
pendix, Fig. S11B), and helminth-elicited Th2 cells (SI Appendix,
Fig. S11C), we selected five candidate miRNAs for further
analysis: miR-15a, miR-20b, miR-146a, miR-155, and miR-200c
(SI Appendix, Fig. S11E). In line with the diversity of in vitro and
ex vivo Th2 populations, not all candidate miRNAs were regu-
lated in a similar manner. For example, both miR-146a and miR-
15a were down-regulated in Th2 cells generated in vitro but were
up-regulated in ex vivo HDM- or helminth-elicited Th2 cells (SI
Appendix, Fig. S11F), again highlighting the disparity between in
vitro and ex vivo Th2 populations.
We identified several mRNA targets of the candidate miRNAs
that have been implicated in Th2 cell biology. For example,
miR-146a was predicted to target the IL-4–regulated genes
Abl2, Kdm6B, and Mtdh (38) in both helminth-derived (H.p.1°)
and in vitro-derived Th2 samples. miR-146a also was predicted
to target Itch (39), Stat1 (40), and Smad4 (41) in all ex vivo Th2
cells (SI Appendix, Fig. S13). miR-15a was predicted to target the
antiapoptotic gene Bcl2 and TGF-β–associated Smad5 in all Th2
samples and, along with miR-155, was predicted to target the
metabolic regulators Sgk3 (42) and Rictor (43), suggesting that
these genes are tightly controlled in Th2 cells by two independent
miRNAs (SI Appendix, Fig. 13B). miR-155 also was predicted to
target Il6r, S1pr1, and Tia-1, all of which have critical roles in Th2
cell biology (44–46). For the down-regulated miRNA candidates
(miR-200c and miR-20b), we identified a significant number of
common mRNA targets, including Gfi1, Maf, Egr2, Hif1α, Lif,
Map3k8, Rorα, and Tnfsf11 (SI Appendix, Fig. S13C), all of which
have reported roles in Th2 cells.
Spatial and Temporal Expression of miRNAs and Their mRNA Targets
in Th2 Cells. We hypothesized that the discrepancy between
miRNA expression patterns in the in vitro-generated and ex vivo
Th2 cells reflected different stages of differentiation or matu-
ration. Therefore we analyzed the temporal expression of the
five candidate miRNAs in FACS-purified, Th2-commited IL4gfp+
cells at early (day 2, 3, and 7) and late (day 10 and 14) stages of
Th2 differentiation in vitro (SI Appendix, Fig. S12A). At day 2,
the expression of miR-155 was elevated, but the expression of
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miR-146a, miR-15a, miR-20b, and miR-200c was down-regu-
lated relative to naive T cells (SI Appendix, Fig. S12B). By day 7,
miR-155 declined, but other miRNAs increased, peaking at day
10. Th2-associated genes (Gata3, Stat6, Il4, Il5, and Il13) were
prominent from day 2 onwards. Concomitantly, several predicted
targets of miR-155 (Sgk3, Il6r, Rictor, and S1pr1), miR-15a
(Tia1), miR-146a (Itch, Stat1, and Smad4), and miR-20b (Egr2,
Lif, Rorα, and Tnfaip3) had an inverse expression pattern at
several time points (SI Appendix, Fig. S12B), supporting a func-
tional interaction. Focusing on miR-155 and miR-146a, we also
observed a temporal relationship between miRNA and mRNA
target expression in purified ex vivo Th2 cells from the in-
flammatory site [airspaces, obtained by bronchoalveolar lavage
(BAL)] and local lung-draining lymph nodes (tLN)] of mice with
HDM-induced airway inflammation. Higher relative levels of
miR-155 in the tLN correlated with lower S1pr1 and Rictor levels
relative to Th2 cells from the BAL, whereas higher miR-146a in
BAL Th2 cells correlated with lower Stat1 and Itch levels than
found in tLN Th2 cells (SI Appendix, Fig. S12C).
To test formally whether miR-155 or miR-146a regulate their
predicted targets in Th2 cells, we transfected FACS-purified
7-d polarized IL4gfp+ Th2 cells (Fig. 2A) either with miR-155
hairpin inhibitors to reduce the elevated levels of miR-155 or
with miR-146a miRNA mimics to increase the down-regulated
levels of miR-146a (SI Appendix, Fig. S12A). miR-155 inhibitors
reduced miR-155 expression without compromising cell viability
(Fig. 2B) and resulted in elevated S1pr1 and Rictor expression
(Fig. 2C). Furthermore, miR-155 inhibitors also reduced IL-13
and IL-5 protein secretion from Th2 cells (Fig. 2E), suggesting
that miR-155 contributes to Th2 effector function. miR-146a
mimicked elevated miR-146a expression and reduced Itch and
Stat1 (Fig. 2D) and slightly increased Il5 and Il13 mRNA ex-
pression (Fig. 2 E and F) but did not impact IL-5 or IL-13 se-
cretion significantly. This discrepancy in mRNA and protein
secretion may be caused by the timing of miRNA treatment and
differential impact on translation and mRNA decay (47). Taken
together, these data reveal the dynamic expression pattern of
several miRNAs and their mRNA targets in vitro and from
different tissues ex vivo and suggest that miR-155 and miR-146a
promote and regulate Th2 cells, respectively.
T-Cell–Intrinsic miR-146a Regulates Th2-Mediated Immunity and Allergy.
miR-146a was regulated dynamically in Th2 cells in vitro (SI
Appendix, Fig. S12A) but was elevated consistently in ex vivo Th2
cells (SI Appendix, Fig. S11F). To test formally whether miR-
146a is required for Th2-mediated immunity in vivo, we gener-
ated T-cell chimeras using miR-146a–deficient bone marrow,
restricting miR-146a deficiency to T cells (Fig. 3A). miR-146a
has been implicated in Treg cells (16); however, in our T-cell
chimeras a normal frequency of Treg and Th cells was observed
(SI Appendix, Fig. S14B), without any signs of autoimmunity.
Following HDM airway challenge, mice with miR-146a−/− T cells
had increased airway infiltrates, with more eosinophils and sig-
nificantly more neutrophils (Fig. 3B). Elevated eosinophils and
neutrophils were accompanied by elevated Il5, Il13, Il17a, and
Ifnγ mRNA in the lung (Fig. 3C). Mice with miR-146a−/− T cells
also had elevated Muc5ac expression (Fig. 3C) and greater in-
terstitial and per-vascular inflammation following HDM chal-
lenge (Fig. 3D), suggesting that T-cell–intrinsic miR-146a is
required to regulate a polarized Th2 response. To determine the
phenotype of HDM-elicited miR-146a−/− T cells, we isolated
CD4+CD44+ miR-146a−/− and CD4+CD44+ miR-146a+/+ T cells
from HDM-allergic mice. As predicted, miR-146a−/− T cells had
elevated miR-146a–targeted genes, i.e., Itch, Smad4, and Stat1,
relative to their miR-146a–sufficient counterparts (Fig. 3E),
again indicating that these genes are miR-146a targets and sug-
gesting that these dysregulated miR-146a targets may contribute
to the increased inflammation.
Unlike H. polygyrus, expulsion of the intestinal whip worm
Trichuris muris is critically dependent on a highly polarized Th2
response (48), and a mixed Th1/2/17 response leads to chronic
infection (49). Therefore we tested whether mice with miR-
146a−/− T cells could mount the polarized Th2 response required
for proficient antihelminth immunity. In line with observations
made in the HDM-allergy model, mice with miR-146a–deficient
T cells had a compromised Th2 response following infection with
T.muris; reduced IL-13+ but elevated IL-17A+ T cells resulted in
significantly more worms present in the cecum (Fig. 3F). Simi-
larly, mice with miR-146a−/− T cells had elevated IFN-γ+ and
IL-17A+ and compromised IL-5+ CD4+ T cells following infection
with H. polygyrus (Fig. 3G), resulting in greater intramuscular in-
flammation and mucus secretion (Fig. 3H). In summary, after
HDM challenge or helminth infection the deletion of miR-146a in
T cells led to a mixed Th1/Th2/Th17 response, suggesting that
miR-146a regulates the polarized differentiation of cells and,
importantly, regulates the differentiation of Th1 and Th17 cells
in otherwise Th2-dominated environments.
T-Cell–Intrinsic miR-155 Is Required for Th2-Mediated Immunity and
Allergy. miR-155 was elevated in whole-lung tissue from HDM-
allergic mice (Fig. 4A) and also was elevated in HDM-elicited and
in vitro-generated Th2 cells (SI Appendix, Fig. S11F). Therefore
we tested the function of miR-155 in vivo using miR-155−/− mice
and observed dramatically reduced airway inflammation, with re-
duced eosinophilia (Fig. 4B) and IL-13 production (Fig. 4C).
Consequently, IL-13–regulated Gob5 expression (Fig. 4D) and
airway mucus production (Fig. 4E) were reduced in miR-155−/−
mice, indicating that miR-155 is essential for Th2-mediated airway
allergy. miR-155 also was elevated in the intestinal tissue of H.
polygyrus-infected mice (Fig. 4F), specifically within the intestinal
lesions around larvae (Fig. 4G), and in H. polygyrus-elicited Th2
cells (SI Appendix, Fig. S11F). In contrast to miR-155–sufficient
mice, miR-155−/− mice were completely susceptible to a challenge
A B
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Fig. 2. miR-155 and miR-146a regulate discrete targets in differentiated Th2
cells. (A) In vitro-generated IL4gfp+ Th2 cells were FACS purified at day 7 of
culture in vitro and were transfected with miR-155 short hairpin inhibitors or
miR-146amimics (100 nM) to reverse the expression profile observed at day 7. (B)
Cell viability at day 10 of culture in vitro, determined by AlamarBlue fluores-
cence. (C) Expression of miR-155 and miR-155 target genes at day 10, expressed
relative to mock-treated cells. (D) Expression of miR-146a and miR-146a–target
genes at day 10, expressed relative tomock-treated cells. (E) IL-13 secretion (Left)
and Il13mRNA (Right) at day 10. (F) IL-5 secretion (Left) and Il5mRNA (Right) at
day 10. Results from one of three independent experiments are shown.
E3084 | www.pnas.org/cgi/doi/10.1073/pnas.1406322111 Okoye et al.
infection with H. polygyrus (Fig. 4H) and failed to develop Th2-
dependent immunity (IL-13 and IL-5) (Fig. 4I) with reduced
goblet cell hyperplasia (Fig. 4J). miR-155−/− mice were fully ca-
pable of mounting a protective Th1 response following blood-
stage P. chabaudi infection, indicating that miR-155 is not re-
quired for a proficient Th1 response (SI Appendix, Fig. S15).
Together, these data indicate that miR-155 is critical for mucosal
type-2 immunity in the lung after HDM challenge and in the gut
after H. polygyrus infection but is not required for tissue Th1
responses after Plasmodium infection.
To test whether T-cell–intrinsic miR-155 is required for type-2
immunity, we generated T-cell chimeras restricting miR-155
deficiency to T cells (Fig. 4K), similar to the miR-146a studies
described above (Fig. 3). Despite comparable T-cell chimerism
(Fig. 4L) without any appreciable change in baseline T-cell
populations (SI Appendix, Fig. S14), miR-155−/− T cells failed to
orchestrate HDM-induced airway inflammation with reduced
airway infiltrates (Fig. 4M), eosinophilia (Fig. 4N), and IL-13
production in the lung (Fig. 4O). Mice with miR-155−/− T cells
also had reduced il5, il13, and Gob5 mRNA in the lung (Fig. 4P)
and reduced goblet cell hyperplasia, phenocopying complete
miR-155−/− mice (Fig. 4 A–E). T-cell–intrinsic miR-155 also was
required for fully proficient Th2-dependent immunity in the
gut, because mice with miR-155−/− T cells had compromised
worm expulsion (Fig. 4R) and goblet cell hyperplasia (Fig. 4S)
after H.p. 2° infection [albeit to a much lesser extent than
complete miR-155−/− mice (Fig. 4B)], indicating that non–T-cell–
expressed miR-155 also contributes significantly to type-2 im-
munity. Finally, miR-155−/− T cells isolated from helminth-
infected mice had elevated miR-155 targets, S1pr1 and Rictor,
relative to miR-155–sufficient T cells (Fig. 4T), suggesting that
dysregulated S1p–S1pr1 interactions (45) or Rictor-associated
metabolic pathways (50) in miR-155−/− T cells may contribute to
the compromised Th2 response.
Directly Targeting miR-155 in Th2 Cells Prevents Th2-Mediated Airway
Allergy. Following the observation that miR-155–deficient mice
and more specifically mice with miR-155–deficient T cells had
a reduced capacity to mount Th2 responses in vivo, we next
tested whether miR-155 could be targeted specifically within
differentiated Th2 cells and whether such targeting would com-
promise Th2 effector function. For these tests, we polarized and
FACS purified OVA-reactive Il4gfp+ Th2 cells using CD45.2
C57BL/6 OTII mice backcrossed onto the Il4gfp background (Fig.
5A). We then knocked down miR-155 in OTII Th2 cells using
miR-155 hairpin inhibitors and adoptively transferred these cells
into congenic CD45.1 C57BL/6 mice (Fig. 5A). Targeting miR-
155 in Th2 cells reduced the capacity of Th2 cells to orchestrate
airway inflammation with reduced airway infiltrates (Fig. 5B),
airway eosinophilia (Fig. 5C), and IL-13 production (Fig. 5D),
thus confirming that miR-155 is required for Th2 effector
function in vivo. miR-155–sufficient Th2 cells caused peribron-
chial inflammation with airway mucus production (Fig. 5E) after
OVA challenge. However, OTII Th2 cells with reduced miR-155
caused much less tissue inflammation and mucus secretion (Fig.
5E), with reduced Gob5 and Muc5ac expression in the lung tis-
sue. Similarly, the IL-4– and IL-13–regulated genes Fizz-1 and
Arg-1 were reduced significantly when miR-155 was targeted in
Th2 cells (Fig. 5F).
miR-155 Regulates S1pr1 in Th2 Cells, Preventing Th2-Mediated
Airway Allergy. Ex vivo and in vitro-generated Th2 cells had an
inverse relationship between miR-155 and several mRNA tar-
gets, including S1pr1 (SI Appendix, Fig. S12). Similarly, miR-155
inhibition in WT Th2 cells dysregulated S1pr1 expression (Fig.
2), suggesting that miR-155 regulates S1pr1. We confirmed that
miR-155 regulates S1pr1 directly using miR-155 miRNA mimics
and a dual luciferase reporter assay with the 3′ UTR of S1pr1
(Fig. 6A). Furthermore, unlike WT Th2 cells which down-regu-
lated S1pr1 upon activation in vitro, miR-155−/− Th2 cells failed
to down-regulate S1pr1 following activation (Fig. 6 B and C).
These observations all indicate that miR-155 regulates S1pr1 in
Th2 cells. To test whether miR-155–regulated S1pr1 contributed
to the compromised Th2 responses in vivo, we treated OVA-
reactive Th2 cells in vitro with miR-155 inhibitors or with siRNA
directed against S1pr1 (SI Appendix, Fig. S16) or with both miR-
155 inhibitors and S1pr1 siRNA. Cell viability was not compro-
mised (Fig. 6D) for up to 48 h after treatment. Inhibition of miR-
155 in Th2 cells (Fig. 6E) led to up-regulated S1pr1 (Fig. 6F), as
observed earlier (Fig. 2). S1pr1 siRNA combined with miR-155
inhibition reduced the elevated levels of S1pr1 (Fig. 6F). We
used this strategy to test whether miR-155–regulated S1pr1 is
an important downstream target of miR-155 contributing to the
reduced airway inflammation that we observed in miR-155−/−
mice (Fig. 4) and more specifically in miR-155–depleted Th2
cells (Fig. 5). We adoptively transferred OVA-reactive Th2 cells
into WT mice following inhibition of either miR-155 or S1pr1
siRNA or inhibition of both miR-155 and S1pr1 siRNA. Mice
were challenged subsequently by intratracheal (i.t.) delivery of
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Fig. 3. T-cell–intrinsic miR-146a regulates the phenotype and magnitude of
Th2-driven immunity and inflammation. (A) Schematic representation of the
generation of miR-146a mixed T-cell bone marrow chimeric mice. (B) Total
number (Left) and composition (Center and Right) of BAL cells following
HDM challenge. (C) Expression of Il5, Il13, Il17a, Ifnγ, andMuc5a/c in the lung
of HDM-challenged mice. (D) H&E-stained lung of HDM-challenged mice. (E)
Expression of miR-146a target genes Itch, Smad4, and Stat1 in WT and
miR-146a− /− CD4+CD44+ T cells from the lungs of HDM-challenged mice,
expressed relative to WT T cells. (F) (Left) Total T. muris worm counts in the
colon and large intestine on day 27. (Center and Right) Frequency of IL-17+
and IL-13+ CD4+ T cells in the local lymph nodes of mice infected with
T. muris. (G) Frequency of IL-5+, IFN-γ+, and IL-17+CD4+ T cells in the local
lymph nodes of mice infected with H. polygyrus. (H) Mucus staining (AB-PAS)
of small intestine of mice infected with H. polygyrus. (Magnification: 20×.)
Five mice per group were used; results of one of three to five experiments
are shown. *P < 0.05, using a nonparametric Mann–Whitney test.
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OVA to reactivate OTII cells in the lower airways. Mice given
miR-155–inhibited Th2 cells had significantly fewer airway
eosinophils (Fig. 6G) and less mucus production (Fig. 6 H and I)
after OVA challenge than mice treated with control Th2 cells.
However, treatment with S1pr1 siRNA and miR-155 inhibitors
significantly reversed the inhibition of airway disease, partially
restoring airway eosinophilia, goblet cell hyperplasia, and mucus
hypersecretion after OVA challenge. Using congenic and T-cell
receptor (TCR) (Vβ5 and Vα2) markers to track adoptively
transferred OTII cells, we observed that miR-155 inhibition
significantly reduced the recruitment of OTII Th2 cells into the
BAL fluid and lungs but not into the local-draining lymph nodes
(Fig. 6J). Compromised recruitment of Th2 cells to the lungs
again was partially, but significantly, reversed when miR-155
inhibition was combined with S1pr1 siRNA (Fig. 6J), indicating
that miR-155–regulated S1pr1 contributes significantly to Th2
cell migration and Th2-mediated airway disease.
In summary, these data indicate that T-cell–intrinsic miR-155
is required for Th2-mediated immunity. Mechanistically, miR-
155 targeted several genes in Th2 cells, including S1pr1, which
contributed significantly to Th2-mediated airway disease. Taken
together, these data suggest that targeting miR-155 could alle-
viate Th2-mediated airway allergy, identifying miR-155 as a pu-
tative therapeutic target to treat allergic asthma.
Discussion
Here we present a systematic and comprehensive analysis of
miRNAs in purified reporter-positive Th1, Th2, Th17, and Treg
cells in vitro and ex vivo from five in vivo disease models. Ap-
plying a subtractive comparative analysis, we identified many
putative miRNAs and their mRNA targets in pathogenic, pro-
tective, and in vitro-generated Th2 cells. These analyses gener-
ated two candidate miRNAs, miR-155 and miR-146a, which
were expressed dynamically in Th2 cells and targeted a suite of
previously unidentified genes. Contrary to in vitro predictions,
we provide in vitro and in vivo experimental evidence supporting
a T-cell–intrinsic role for miR-155 and miR-146a in promoting
and regulating Th2 immunity, respectively. Mechanistically, miR-
155–regulated S1pr1 in activated Th2 cells contributes to Th2-
mediated airway inflammation.
Purified reporter-positive cells gave significantly greater
resolution and contrast to the transcriptome of T-cell subsets
as compared with bulk, whole-well analysis. This approach
identified several previously reported miRNAs (19) and many
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Fig. 4. T-cell–intrinsic miR-155 is required for Th2-
dependent antihelminth immunity and Th2-driven
airway inflammation. (A) Expression of miR-155 in the
lung of PBS- or HDM-challenged mice. (B) Total
number (Left) and composition (Right) of cells re-
covered by BAL from the airways of HDM-challenged
mice. (C) IL-13 secretion from HDM-restimulated tLN
cells. (D) Expression of Gob5 in HDM-challenged mice.
(E) Mucus staining (AB-PAS) of HDM-challenged lungs
at 2×, 5×, and 10× magnification. (F) Expression of
miR-155 in the small intestine of H. polygyrus-infec-
ted mice (day 14) relative to naive mice. (G) FISH
showing the presence of miR-155 in gut tissue sur-
rounding H. polygyrus larvae. (H) Total worm burden
of mice following drug cure and challenge infection
(H.p. 2°). (I) Frequency of IL-13+CD4+ T cells in local
draining lymph nodes of H. polygyrus-infected mice.
(J) Mucus staining (AB-PAS) of small intestine fol-
lowing H.p. 2° infection. (K) Schematic representation
of the generation of miR-155 mixed T-cell bone
marrow chimeric mice. (L) Splenic CD4+ T-cell num-
bers. (M and N) Total BAL cell numbers (M) and
composition (N) following HDM challenge of chimeric
mice. (O) IL-13 protein levels in culture supernatants
of restimulated thoracic lymph nodes. (P) Expression
of Il5, Il13, and Gob5 in lungs of chimeric mice fol-
lowing HDM challenge. (Q) Mucus staining (AB-PAS)
of HDM-challenged lungs. (R) Total worm burden of
mice following drug cure and challenge infection
(H.p. 2°). (S) Mucus staining (AB-PAS) of small intestine
followingH.p. 2° infection. (T) Expression of S1pr1 and
Rictor in WT and miR-155−/− CD4+ T cells isolated from
H. polygyrus-infected mice. Five mice per group
were used. Results of one of three to five experiments
are shown. *P < 0.05, using a nonparametric Mann–
Whitney test.
E3086 | www.pnas.org/cgi/doi/10.1073/pnas.1406322111 Okoye et al.
more previously unidentified miRNAs in all Th subsets in vitro
and ex vivo. Strikingly, in vitro-generated cells had little tran-
scriptional resemblance to ex vivo-isolated cells, which may be
influenced by tissue- (gut or lung) or stimuli- (allergen or hel-
minth) specific signals. Thus, therapies targeting Th2 or other
T cells may require disease-specific approaches. Despite such
heterogeneity, this approach also identified a core set of 82
Th2-associated genes (fivefold change, 5.14%) in common,
including genes involved in IL-5 signaling and immune cell
trafficking [Egln3, IL1r2 (38), Il2, IL1rl1 (Il33r), Ccl1, Rgs1,
and Socs2], and metabolic and environmental sensing (Cst7,
stx11, Ahr, Hsp70); IL-4 signaling [Ctla2, Nfil3 (51)] and genes
that regulate IL-4, IL-10, and IL-2 secretion [Tnfsf14 (Light),
Nfil3, and Socs2 (52)].
miR-146a regulates many functions in innate and adaptive
immune cells (53), with miR-146a−/− mice suffering from a my-
eloproliferative disorder (54). In vitro-differentiated Th2 cells
had decreased miR-146a at day 7, after an initial spike at day 2
(SI Appendix, Fig. S12), similar to a previous report (55). How-
ever, all ex vivo Th2 cells had elevated miR-146a, again high-
lighting the disparity in miRNA expression between in vitro and
ex vivo Th2 cells.
Importantly, in vivo we observed a regulatory role for T-cell–
intrinsic miR-146a, with miR-146a−/− T cells giving rise to a
mixed and more aggressive type-1/2/17 response following al-
lergen challenge or helminth infection, an observation in line
with previous studies (15, 56). Of note, when miR-146a de-
ficiency was restricted to Treg cells, but not Th cells, miR-146a
was required for Treg function (16). In our experiments, mice
with miR-146a−/− T cells had a normal frequency of Treg cells
and did not display any autoimmunity-associated pathology be-
fore infection or allergen challenge. Our in vivo data therefore
support a Th cell-intrinsic role for miR-146a, similar to other
reports (15), rather than a Treg defect (16).
Several miR-146a targets were inversely expressed with miR-
146a in Th2 cells, including Irak2, Traf6 (57), and Stat1 (16). We
also identified Itch, an E3 ubiquitin ligase, as a common target
of miR-146a in all ex vivo Th2 cells. Itch also was inversely
expressed with miR-146a at day 2 and day 7 of Th2 polarization
in vitro (SI Appendix, Fig. S12) and was elevated in miR-146a−/−
T cells ex vivo. Itch regulates cytokine production and activation
of Th2 cells (39) and is required for Th2 tolerance (58). Here, we
propose an additional mechanistic pathway of miR-146a–medi-
ated regulation of Itch, preventing an aggressive Th2 and Th1/17-
mediated response. Elevated miR-146a has been observed in T
cells from patients with arthritis (59) and T-cell leukemia (60), and
polymorphisms in miR-146a are associated with asthma (61).
However, as we report here, elevated miR-146a may be regulating
rather than contributing to T-cell malignancies and should be
therapeutically targeted with caution.
As mentioned above, we observed dynamic miRNA expression
in Th2 cells in vitro. These observations, combined with little
overlap between in vitro and ex vivo cells, indicate that caution
must be taken when translating in vitro miRNA observations to
in vivo settings. Indeed, it has been reported that miR-155 reg-
ulates Th2 cell differentiation in vitro, with slightly enhanced
Th2 differentiation in miR-155−/− T cells in vitro (34, 62). These
observations predicted that miR-155 functions as a negative
regulator of Th2-differentiation and Th2 immunity. However, as
we report here, in vitro observations of miR-155 in T cells did
not predict in vivo function, because miR-155 was required for
type-2 responses, and, more specifically, T-cell–intrinsic miR-155
was essential for competent type-2 immunity. Thus, contrary
to in vitro predictions, specifically targeting miR-155 may block
rather than exacerbate the progression of T-cell–mediated air-
way allergy and asthma.
Although miR-155 regulates both innate and adaptive respon-
ses (63), miR-155 may be a promising target for other hyper-
inflammatory T-cell–mediated diseases including colitis (64) and
autoimmunity (65), with the potential caveat that intestinal Th1/
17-mediated immunosurveillance may be compromised (64). miR-
155 also is required for optimal Treg proliferation in vivo (66),
suggesting that miR-155 may function as a broad regulator of
T-cell expansion. This notion is supported by transgenic miR-155
overexpression studies, which led to aggressive and disseminated
lymphomas (67), underlining the oncogenic properties of dysre-
gulated miR-155 (68). However, miR-155−/− mice could mount a
sufficient and protective splenic Th1 response after Plasmodium
infection (SI Appendix, Fig. S15), suggesting that miR-155 may
critically regulate homing, migration, or mucosal T-cell responses,
irrespective of T-cell phenotype.
Allergen-exposed peripheral blood mononuclear cells from
patients with atopic dermatitis also up-regulated miR-155 (69),
which correlated with reduced CTLA-4 and increased pro-
liferation. Whether a miR-155–CTLA-4 axis is responsible for the
hyperproliferative role of miR-155 is unclear. We identified sev-
eral putative targets of miR-155, including the metabolic regu-
lators Sgk3 (42) and Rictor (43) and also Il6r, S1pr1, and Tia-1.
Although Rictor is critical for T-cell development (70) and Th2
differentiation in vitro (50), we observed a down-regulation of
Rictor in Th2 cells in vitro with a concomitant increase in miR-155.
In line with this observation, Rictor was elevated in ex vivo miR-
155−/− T cells from helminth-infected mice (Fig. 4T). These data
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Fig. 5. Targeting miR-155 in Th2 cells prevents Th2-mediated airway al-
lergy. (A) Schematic representation of the adoptive transfer system used.
Naive CD4 cells from IL-4gfpCD45.2 C57BL/6 OTII mice were polarized under
Th2 conditions, as described in Materials and Methods, and were FACS sor-
ted on IL4gfp. Cells then were mock transfected (control) or transfected with
100 nm of miR-155 short hairpin inhibitors before 106 cells were adoptively
transferred i.v. into recipient CD45.1 mice. Recipient mice were given OVA
i.t. as described inMaterials and Methods. Adoptively transferred cells could
be found in the lung and local lymph nodes of recipient mice. (B and C) Total
BAL cells (B) and BAL eosinophils (C) were enumerated in BAL fluid of mice
1 d after the last OVA challenge. (D) OVA-induced IL-13 was measured in
OVA-stimulated local lymph nodes. (E ) H&E-stained (Upper row) and
AB-PAS–stained (Lower row) lung sections. (Magnification: 20×.) (F) Gene
expression in whole-lung tissue following OVA challenge, expressed relative
to OVA-challenged mice that did not receive Th2 cells.
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suggest that low, but not absent, levels of Rictor are sufficient for
Th2 cell differentiation and that miR-155–regulated Rictormay be
required for proficient Th2 responses.
Following activation, lymphocyte egress from lymphoid tissue
requires the down-regulation of S1pr1 (45). We observed a rapid
down-regulation of S1pr1 in activated Th2 cells in vitro with
a concomitant increase in miR-155 (SI Appendix, Fig. S12),
suggesting that miR-155 targets S1pr1. Indeed, miR-155−/−
T cells isolated ex vivo had elevated S1pr1 (Fig. 4), further
supporting the notion that miR-155–regulates S1pr1. In vitro,
dual luciferase reporter assays confirmed that miR-155 directly
regulates S1pr1, whereas in vivo studies using purified Th2 cells
confirmed that, although miR-155 targets several genes in Th2
cells, miR-155–regulated S1pr1 is required for Th2-mediated
airway inflammation, possibly via controlling Th2 migration to
the lung. These data identify a previously unknown function of
miR-155 in regulating Th2 cell migration through control of
S1pr1 expression and provide an miRNA-mediated upstream
mechanistic pathway explaining the importance of S1pr1 in Th2
cell biology (71, 72).
In conclusion, this study provides a comprehensive analysis of
miRNA expression in highly purified reporter-positive T cells,
highlighting the disparities between in vitro and ex vivo T cells,
and functionally demonstrates the opposing roles of miR-155
and miR-146a in Th2-mediated allergic and helminth-induced
immunity. The miR-155–mediated pathways regulating Th2 cell
activation and egress and fulminant type-2 immunity suggest that
targeting miR-155, but not miR-146a, may help shape new
strategies targeting specific miRNAs to treat allergic asthma and
other Th2-mediated diseases.
Materials and Methods
Animals. C57BL/6, 129S8.B6 (F1), C57BL/6.Tcratm1 Phi, Rag2−/−, Il4gfp (IL4/GFP-
enhanced transcript; 4get) (73), Il9CreR26eyfp, Il17aCreR26FP635 [kindly pro-
vided by Brigitta Stockinger, Medical Research Council, National Institute for
Medical Research (NIMR), London], Ifnγeyfp (YETI), Foxp3rfp, and miR-155−/−
andmiR-155+/+ littermates were bred and kept in the specific pathogen-free
facility at the NIMR.miR-146a−/− bone marrow was kindly provided by David
Baltimore (Braun Laboratories, California Institute of Technology, Pasadena,
CA). Mice were randomly separated into cages containing five mice before
the experimental procedure. All animal experiments were approved by local
and national ethical review panels at NIMR and were carried out under UK
Home Office regulations (Project License no. 80/2506). All mice were 6–8 wk
old at the onset of experiments. A minimum of five mice per group was used
for each experiment, unless otherwise indicated.
Generation of Mixed T-Cell Bone Marrow Chimeric Mice. Six- to eight-week-old
mice were sublethally irradiated (2×, 450 rad) followed by adoptive transfer
of 2–5 × 106 bone marrow cells (20% bone marrow from miR-146a−/−, miR-
155−/−, or WT donor mice with 80% bonemarrow from C57BL/6.Tcratm1 Phi mice).
Mice were given water ad libitum supplemented with Baytril (Bayer) for
3 wk after radiation.
CD4 T-Cell Isolation and Flow Cytometry. CD4+ T cells were isolated from
tissues by mechanical disruption followed by red blood cell lysis and Percoll
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Fig. 6. miR-155 regulates S1pr1 in Th2 cells, preventing Th2-
mediated airway allergy. (A) Jurkat T cells were transfected
with dual luciferase reporter clones containing 1 nM of either
the 3′ UTR of S1pr1 or a control 3′ UTR. Cells also were
cotransfected with either miR-155 mimics (100 nM) or a
scrambled miRNA control (−). Relative fluorescent units (RFU)
were determined after 24 h. (B and C) Seven-day Th2 cells were
generated from WT or mir-155−/− mice and left to rest for
a further 48 h. Cells then were stimulated with plate-bound
anti-CD3 and anti-CD28 for 12 h before miR-155 and S1pr1
levels were measured by qRT-PCR. (D–F) Naive CD4+ cells from
IL-4gfpCD45.2 C57BL/6 OTII mice were polarized under Th2
conditions, as described in Materials and Methods, and were
FACS purified using IL4gfp. Th2 cells then were transfected with
either miR-155 inhibitors (+; 100 nM) or scrambled control
miRNA (c; 1 nM) and with S1pr1 siRNA (+; 1 nM) or control
siRNA (100 nM), as indicated. Cells were cultured for 48 h to
determine the impact of transfection on cell viability (D) or for
24 h to determine miR-155 (E) or S1pr1 (F) expression. (G–J) Th2
(Il4gfp+CD45.2 C57BL/6 OTII) cells transfected with either miR-
155 inhibitors (+; 100 nM) or scrambled control miRNA (c; 1 nM)
and with S1pr1 siRNA (+;1 nM) or control siRNA (c; 100 nM), as
indicated, were adoptively transferred into the tail veil of WT
mice (day 1), 1 d after an intratracheal delivery of OVA (day −1).
Mice received two further OVA airway challenges on day 2 and
day 4. Airway pathology was assessed on day 5. (G) Airway eo-
sinophilia was determined in BAL fluid. (H and I) Lungs were
stained with AB-PAS to determine airway goblet cell and mucus
secretion (H), and results were quantified using qRT-PCR (I). (J)
Single-cell suspensions of lungs and local lung-draining lymph
nodes were stained for congenic (CD45.2) and T-cell receptor
markers (Vβ5 and Vα2) to identify Th2 OTII cells in the BAL, lung,
and lymph nodes.
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(Sigma Aldrich) gradient separation followed by positive or negative cell
enrichment using magnetic beads (L3T4; Miltenyi Biotec). Cells then were
stained with anti-mouse CD4 (clone RM4-5), CD44 (clone IM7), CD25
(clone PC61), TCR-β (clone H57-597), Vβ5 (clone MR9-4), and Vα2 (clone
B20.1). Dead cells were excluded from sorting and analysis with pro-
pidium iodide or Live/Dead stain (Invitrogen). For intracellular cytokine
staining, anti–IFN-γ (clone XMG1.2), IL-4 (clone 11B11), IL-5 (clone
TRFK5), IL-13 (clone eBio 13A), IL-17 (clone TC11-18H10), and anti-Foxp3
(clone FKJ-16s) (BD and eBioscience) were used after 6 h of stimulation
with PMA (50 ng/mL), ionomycin (1 μg/mL), and Golgistop/Golgi plug (10
μg/mL) (BD Biosciences) with Fix/Perm buffer (eBioscience) and Perm/
Wash buffer (eBioscience) used according to the manufacturers’
instructions. Anti-CD16/32 was used in all staining. Cells were acquired
using a BD LSRII and analyzed with FlowJo software (Treestar). For cell
sorting, BD Influx, FACSAria (BD), or MoFlo XDP (Beckman Coulter) sorters
were used; the purity of sorted cells was >95%.
In Vitro Th Cell Polarization. T cells were polarized under the following
conditions: Th1: IL-12 (10 ng/mL), anti–IL-4 (10 ug/mL); Th2: IL-4 (10 ng/mL),
IL-2 (5 ng/mL), anti–IFN-γ (10 μg/mL); Th17: IL-6 (10 ng/mL), TGF-β (1 ng/mL),
IL-1β (10 ng/mL), 6-formylin-dolo (3,2-b) carbazole (250 nm), anti–IL-4, anti–
IFN-γ, anti–IL-2 (10 μg/mL); Th9: IL-6 (10 ng/mL), IL-4 (10 ng/mL), TGF-β (5 ng/mL),
IL-1β (10 ng/mL), anti–IFN-γ (10 μg/mL); iTreg: TGF-β (5 ng/mL), anti–IL-4, anti–
IFN-γ (10 μg/mL). Bulk or FACS purified reporter-positive in vitro Th cells
were harvested on day 7, or as indicated. All recombinant cytokines and
antibodies were purchased from R&D Research, BioXcell, or Peprotech.
Airway Allergy, EAE, and Infection Models. H. polygyrus. Mice were infected
with 200 H. polygyrus infective larvae (stage 3) by oral gavage. Primary (H.p. 1°)
Il4gfp+CD4+ T cells were FACS sorted on day 14 from mesenteric lymph
nodes. Secondary (H.p. 2°) IL4gfp+ CD4 T cells were recovered from mice on
day 42, following drug cure (day 14) and challenge infection (day 28). Th2-
mediated immunity to H. polygyrus was determined 14 d after secondary
infection, with luminal worms counted in the small intestine.
T. muris. Mice were infected with 200 T.muris eggs (kindly provided by Richard
Grencis, University of Manchester, Manchester, United Kingdom), Worms in
the cecum and large intestine were counted on day 27 postinfection.
HDM-induced airway allergy. For HDM-induced airway inflammation, mice were
sensitized by i.p injection of 100 μg HDM (Greer) with 2 mg of Imject Alum
(Pearce) followed by i.t. challenge with 100 μg HDM in PBS on day 21 and
day 24. Il4gfp+CD4+ T cells were purified from the lung and local lymph nodes
by FACS sorting on day 25. Airway infiltrates were determined on stained
cytospins of BAL recoveries, performed with 1.5 mL of cold PBS.
OTII-Th2–mediated airway allergy. For OVA-induced OTII reactivation in the
airways, 106 IL-4gfp+ OTII cells were FACS purified following in vitro Th2
differentiation and were mock transfected or were transfected with 100 nm
of miR-155 short hairpin inhibitors, S1pr1 siRNA, or control scrambled
miRNA or siRNA, as indicated, and were adoptively transferred into the tail
vein of recipient mice. Recipient mice were given an intratracheal delivery of
OVA (Sigma Grade V), 1 d before cell transfer (day −1) and 1 and 3 d after cell
transfer (day 2 and day 4). Mice were analyzed for evidence of Th2-mediated
disease on day 5.
P. chabaudi. Th1 cells were isolated from Ifnγyfp mice that had received 105
P. chabaudi-infected red blood cells i.p. Ifnγyfp+CD4+ T cells were FACS pu-
rified from spleens on day 7 postinfection. In experiments with miR-155−/−
mice, animals were infected with 105 P. chabaudi-infected red blood cells
and analyzed for their ability to mount protective Th1 responses on day
8–9 postinfection.
EAE. Il17aCreRosa26FP635+ CD4+ T cells were FACS purified from the spinal
cord and lymph nodes of mice with EAE on days 9–12 as described previously
(74). nTregs (CD4+CD25hiFoxp3rfp+) were purified from the spleen of
naive Foxp3rfp mice. For histopathology, lung or gut tissue was fixed in
10% neutral-buffered formalin [4% (wt/vol) formaldehyde] for at least
24 h before being transferred to 70% (wt/vol) ethanol. Tissues were
stained with Alcian blue periodic acid-Schiff (AB-PAS) stain and H&E
stain for detection of mucus production and leukocyte infiltration, re-
spectively. For FISH, tissue was first perfused with 4% paraformaldehyde
(PFA) and stored in 30% (wt/vol) sucrose/PBS solution at 4 °C overnight
before snap freezing and sectioning (10 μm). Tissue was refixed with
4% (wt/vol) formaldehyde and treated with proteinase K before incubation
with digoxigenin-labeled LNA (Exiqon) miRNA probes (miR-155 sequence
ACCCCTATCACAATTAGCATTAA; control sequence, GTGTAACACGTCTATA-
CGCCCA) in hybridization buffer.
Transfection and Dual Luciferase Reporter Assays. T cells were washed,
counted, and resuspended in Nucleofector solution (Lonza) with supple-
ments, according to the manufacturer’s recommendations. miRNA mimics or
inhibitors (100 nM) (Thermo Scientific, Dharmacon) or S1pr1 siRNA or control
siRNA were added to cell suspension, and cells were plated at a density of
2–3 × 105 cells per well in a 96-well Nucleocuvette Plate. Cells were trans-
fected in a 96-well-Shuttle System and left to rest for 3–20 h at 37 °C before
analysis or adoptive transfer, as indicated in figure legends. For dual lucif-
erase reporter assays, Jurkat T cells were transfected with firefly/Renilla Duo-
Luciferase reporter clones containing 1 nM of either the 3′ UTR of S1pr1 or
a control 3′ UTR, using the Nucleofector system (Genecopeia), as above,
according to the manufacturer’s instructions. Cells were cotransfected with
100 nM of either miR-155 mimics or a scrambled miRNA control, as indicated.
Relative fluorescent units were determined 24 h later.
RNA, Quantitative RT-PCR, and Microarray. RNA was isolated from tissues and
cells using RNAeasy mini-spin columns (Qiagen) according to the manu-
facturer’s instructions. cDNA was generated from 5 ng of total RNA using
the WT-Ovation Pico system (version 1) RNA Amplification System followed
by double-stranded cDNA synthesis using the WT-Ovation Exon Module.
cDNA quality was determined by the Systems Biology Unit at the NIMR using
an Agilent BioAnalyzer and through hybridization performance on Affy-
metrix GeneChip mouse Genome 430A 2.0 microarray (Affymetrix) and
miRNA 3.0 arrays (Affymetrix). Microarray data were quantile-normalized
and analyzed using GeneSpring software (Agilent). Differentially expressed
genes were determined using ANOVA and t tests. Genes with false discovery
rate-corrected P values <0.1 and fold change values ≥1.5 were considered
significant, as indicated in figure legends. Three to five biological replicates
of each T-cell subset were used. Four-way comparative analyses, expression-
pairing analyses, target predictions (miRecords, Tarbase, Targetscan), and
target abundance were determined using Ingenuity Pathways Analysis (In-
genuity Systems; www.ingenuity.com). For quantitative RT-PCR (qRT-PCR),
RNA was reverse-transcribed using the miScript II RT Kit (Qiagen). Real-time
RT-PCR was performed on an ABI Prism 7900HT Sequence Detection System
(Applied Biosystems); relative quantities of mRNA or miRNAs were de-
termined using SYBR Green PCR Master Mix (Applied Biosystems) and by the
comparative threshold cycle method as described by Applied Biosystems for
the ABI Prism 7700/7900HT Sequence Detection Systems. mRNA levels were
normalized to hypoxanthine guanine phosphoribosyltransferase (HPRT), and
miRNA levels were normalized to the small nucleolar RNA, RNU6B, and were
expressed as a relative increase or decrease compared with levels in controls
or relative to HPRT or RNU6b, as indicated.
ELISA. Cytokines and IgE were measured by ELISA. Capture and biotinylated
detection antibodies for IL-4, IL-5, IL-13, IFN-γ, IL-17A, and IgE were from R&D
Systems. The concentration of analytes in the sample was determined from
a serial-fold diluted standard curve with OD read at 405 nm in an ELISA
reader (Tecan II Safire).
Statistical Analysis. Datasets were compared by Mann–Whitney test or one-
way ANOVA as specified in the figure legends using GraphPad Prism (V.5.0).
Differences were considered significant at P ≤ 0.05.
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